We have previously reported that as a novel therapeutic target, HHLA2 is overexpressed in human ccRCC tissues, and its expression is significantly associated with the prognosis and cancer progression of the patients [6]. Here, HHLA2 is linked to nonpapillary renal cell carcinoma.